Cargando…

The evolving role of Bruton’s tyrosine kinase inhibitors in chronic lymphocytic leukemia

Ibrutinib, the first in class of the oral covalent Bruton tyrosine kinase (BTK) inhibitors, has profoundly changed the treatment landscape of chronic lymphocytic leukemia (CLL). The phase III RESONATE and RESONATE-2 trials first demonstrated the superiority of ibrutinib over ofatumumab in the relaps...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gordon, Max J., Danilov, Alexey V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Evolving Landscape in Chronic Lymphocytic Leukemia Treatment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7970705/ https://www.ncbi.nlm.nih.gov/pubmed/33796237 http://dx.doi.org/10.1177/2040620721989588

Ejemplares similares

Sialylation regulates migration in chronic lymphocytic leukemia
por: Natoni, Alessandro, et al.
Publicado: (2023)

B-cell antigen receptor expression and phosphatidylinositol 3-kinase signaling regulate genesis and maintenance of mouse chronic lymphocytic leukemia
por: Schmid, Vera Kristin, et al.
Publicado: (2022)

The role of acalabrutinib in adults with chronic lymphocytic leukemia
por: Fakhri, Bita, et al.
Publicado: (2021)

Subgroup-specific gene expression profiles and mixed epistasis in chronic lymphocytic leukemia
por: Lütge, Almut, et al.
Publicado: (2023)

The immunomodulatory molecule TIGIT is expressed by chronic lymphocytic leukemia cells and contributes to anergy
por: Arruga, Francesca, et al.
Publicado: (2023)

Interleukin-27 potentiates CD8(+) T-cell-mediated antitumor immunity in chronic lymphocytic leukemia
por: Pagano, Giulia, et al.
Publicado: (2023)

Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients
por: Brown, Jennifer R., et al.
Publicado: (2021)

A clinical practice comparison of patients with chronic lymphocytic leukemia with and without deletion 17p receiving first-line treatment with ibrutinib
por: Mato, Anthony R., et al.
Publicado: (2022)

First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial
por: Moreno, Carol, et al.
Publicado: (2022)

Genetic predisposition to chronic lymphocytic leukemia
por: Law, Philip J., et al.
Publicado: (2019)

High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 – VERITAS study
por: Mauro, Francesca R., et al.
Publicado: (2023)

Combining novel agents in chronic lymphocytic leukemia: Greater than the sum of its parts?
por: de Weerdt, Iris, et al.
Publicado: (2019)

A novel next-generation sequencing capture-based strategy to report somatic hypermutation status using genomic regions downstream to immunoglobulin rearrangements
por: McCafferty, Neil, et al.
Publicado: (2022)

Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia
por: Flynn, Kathryn E., et al.
Publicado: (2022)

COVID-19 Pandemic Impact on Chronic Lymphocytic Leukemia (CLL) Patients' Preferences Towards Therapies: The Italian Experience (CHOICE Study)
por: Molica, Stefano, et al.
Publicado: (2021)

Cellular Immune Responses to BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia
por: Itchaki, Gilad, et al.
Publicado: (2021)

Humoral Response to mRNA Vaccines BNT162b2 and mRNA-1273 COVID-19 in Chronic Lymphocytic Leukemia Patients
por: Bagacean, Cristina, et al.
Publicado: (2021)

A Clue to Better Select Chronic Lymphocytic Leukemia Patients with Optimal Response to BNT162b2 mRNA COVID-19 Vaccine
por: Molica, Stefano, et al.
Publicado: (2021)

Chronic Lymphocytic Leukemia (CLL) Patients Quality of Life (QoL): A Cross-Sectional Analysis of the Italian Experience in the Choice Study during the First Wave of the COVID-19 Pandemic
por: Tedeschi, Alessandra, et al.
Publicado: (2021)

Chronic myeloid leukemia
por: Hantschel, Oliver
Publicado: (2019)

Immunotherapy in Chronic Lymphocytic Leukaemia (CLL)
por: Freeman, Ciara L., et al.
Publicado: (2016)

Serological Prevalence of Sars-Cov-2 Infection Among Chronic Myeloid Leukemia Patients Undergoing Tyrosine Kinase Inhibitor Treatment in Italy (COVID-19-HEM Study)
por: Bonifacio, Massimiliano, et al.
Publicado: (2020)

CML-127 Results of a Vaccination Against COVID-19 by a Vector Based Vaccine Sputnik V in Patients With Chronic Myeloid Leukemia
por: Chelysheva, Ekaterina, et al.
Publicado: (2022)

CML-384 Immunological Response to SARS-CoV-2 After Infection and/or Vaccination Among Chronic Myeloid Leukemia Patients – A Prospective Study
por: Galvis, Marisol Miranda, et al.
Publicado: (2022)

Non-Covalent Bruton’s Tyrosine Kinase Inhibitors in the Treatment of Chronic Lymphocytic Leukemia
por: Montoya, Skye, et al.
Publicado: (2023)

A rare case of appendicular skeleton localization in a patient with chronic lymphocytic leukemia successfully treated with salvage radiation therapy
por: Tuscano, Carmelo, et al.
Publicado: (2017)

COVID-19 Infection in Vaccinated Adult Patients with Hematological Malignancies. Preliminary Results from Epicovideha (Epidemiology of COVID-19 infection in patients with hematological malignancies: A European Haematology Association Survey)
por: Marchesi, Francesco, et al.
Publicado: (2021)

Poor Neutralizing Antibody Responses in Patients with CLL, NHL and HL after Vaccination Against Sars-Cov-2; A Prospective Study in 132 Patients
por: Terpos, Evangelos, et al.
Publicado: (2021)

A Third Anti-Sars-Cov2 mRNA Dose Does Not Overcome the Pejorative Impact of Anti-CD20 Therapy and/or Low Immunoglobulin Level in CLL/Lymphoma Patients
por: Chbat, Maureen, et al.
Publicado: (2021)

Humoral and Cellular Immunogenicity of COVID-19 Vaccinations in Patients with CLL
por: Sun, Clare, et al.
Publicado: (2021)

Evaluation of Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Immunizations in Patients with B-Cell Malignancies
por: Singal, Mukul, et al.
Publicado: (2021)

Cerebral Invasive Aspergillosis in a Case of Chronic Lymphocytic Leukemia with Bruton Tyrosine Kinase Inhibitor
por: Alkharabsheh, Omar, et al.
Publicado: (2021)

Tyrosine Kinase Inhibitor Therapy Discontinuation for Patients with Chronic Myeloid Leukaemia in Clinical Practice
por: Clark, Richard E.
Publicado: (2019)

Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modeling and pathway analysis
por: Radich, Jerald P., et al.
Publicado: (2023)

Response to imatinib mesylate in childhood chronic myeloid leukemia in chronic phase
por: Linga, Vijay Gandhi, et al.
Publicado: (2014)

When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia
por: Laneuville, Pierre
Publicado: (2018)

Differential inhibition of T-cell receptor and STAT5 signaling pathways determines the immunomodulatory effects of dasatinib in chronic phase chronic myeloid leukemia
por: Harrington, Patrick, et al.
Publicado: (2023)

RHOA-regulated IGFBP2 promotes invasion and drives progression of BCR-ABL1 chronic myeloid leukemia
por: Zhang, Hualei, et al.
Publicado: (2022)

CML-005: Outcome of Haploidentical Hematopoietic Stem Cell Transplantation with a Donor and Recipient with SARS-CoV-2 Infection
por: Ali, Gadallah, et al.
Publicado: (2021)

Cytogenetic and Molecular Predictors of Outcome in Acute Lymphocytic Leukemia: Recent Developments
por: Iacobucci, Ilaria, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_k4g8cap0f5np126fj6g1l46koo